
State Group Health Projections

Long-term cost projections of the GHIP (including impact of COVID-19)



Every 1% of GHIP budget growth (trend) in FY21 increases the FY22 projected budget by an additional \$9.0M. This would require an additional \$8.2M in State Contributions (\$5.5M from the General Fund), and an additional \$0.8M in employee/pensioner contributions.

FY21 Budget and FY22 Projected Expenses reflect estimated financial impact of COVID-19 using available information and reasonable estimation techniques. However due to the high degree of uncertainty associated with this pandemic, results may vary from the estimates provided.

FY21 and beyond projected based on experience through and enrollment as of FY21 Q3 and reflects the following assumptions: includes approved design changes effective 7/1/2019 including implementation of SurgeryPlus COE (\$0.5m annual savings), site-of-care steerage (\$6.9m), Highmark infusion therapy program (\$2.0m) and implementation of Livongo (\$0.7m); includes State and employee/pensioner premium contributions; assumes 1% annual enrollment growth for FY21-FY26; includes Rx rebates and EGWP payments; includes estimated improvements in Rx rebates and reduction in pharmacy claims based on best and final ESI FY20 renewal proposal, provided 1/29/2019; includes fees for participating non-State groups (assumed to increase proportionally with membership growth and health care trend); FY21 reflects implementation of Highmark radiation therapy authorization program (\$633k annual savings per Highmark); assumes no other program changes in FY21 and beyond; projections based on 5% medical, 8% pharmacy trend; reflects FY21 plan savings based on ESI year 5 traditional pharmacy BAFO renewal; FY22 and beyond includes estimated reduction in pharmacy claims as a result of PBM award to CVS Health